Chai Discovery secured $400 million in Series C financing, pushing the company’s valuation to $3.8 billion and expanding its AI-first approach to generating de novo molecular designs. The company said its platform is already used by pharma partners including Eli Lilly and Pfizer, and it released Chai-3, designed to improve binding affinity and target success rates versus prior models.